TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05738148
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC.
Study: NCT05249777
Drug: TD0069 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
Study: NCT04802967
Drug: Ketoprofen Lysine Salt combined with Gabapentin
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
Study: NCT04802967
Drug: Ketoprofen Lysine Salt
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
Study: NCT06798376
Drug: ≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
Study: NCT06798376
Drug: ≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
Study: NCT04971733
Drug: E2814
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2814 intravenous infusion.
Study: NCT05081609
Drug: TransCon IL-2 β/γ
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
Study: NCT05081609
Drug: TransCon TLR7/8 Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
Study: NCT04825171
Drug: Bryophyllum 50 % Chewing Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
Study: NCT06321289
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT04945161
Drug: ON101 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Study: NCT06304545
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine PO oxaliplatin IV
Study: NCT06186401
Drug: Cyclophosphamide (non-investigational)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06056297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered per schedule specified in the arm description.
Study: NCT05944224
Drug: SPH4336
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
Study: NCT06237881
Drug: KSQ-001EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06237881
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06687369
Drug: MB12 (Proposed Pembrolizumab Biosimilar)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV, every 3 weeks on Day 1
Study: NCT06687369
Drug: EU-sourced Keytruda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV, every 3 weeks on Day 1
Study: NCT06687369
Drug: US-sourced Keytruda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV, every 3 weeks on Day 1
Study: NCT05016076
Drug: Placebo (0.9% sodium chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
Study: NCT05180526
Drug: QLETLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Study: NCT06269484
Drug: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)
Study: NCT05568706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take matching placebo, once daily for 5 days
Study: NCT05476484
Drug: SQ SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
Study: NCT06217185
Drug: Taxanes
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes: Usual clinical dose is administered, in a 21-day cycle.
Study: NCT06217185
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 650mg/m2 each time, given twice daily
Study: NCT04655755
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05962606
Drug: AON-D21
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study: NCT05962606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
Study: NCT05586360
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg taken orally daily for 8 weeks
Study: NCT05740813
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo is administered orally once per day for 24 weeks.
Study: NCT05678010
Drug: AZD1390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
Study: NCT06331728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to IGNX001 given as a single subcutaneous dose on Day 1.
Study: NCT05829187
Drug: Momordica Charantia Extract
Normalized name: Momordica charantia stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Study: NCT05132582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally twice daily
Study: NCT05198310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06224348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: injection solution Route of administration: SC injection
Study: NCT06224348
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Topical formulation Route of administration: Topical
Study: NCT06224348
Drug: Topical calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Topical formulation Route of administration: Topical
Study: NCT06524830
Drug: VLS-01-BU Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo buccal transmucosal administration
Study: NCT04843852
Drug: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Normalized name: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 0.5ml intramuscular injection on day 0 and week 4.
Study: NCT05832827
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
Study: NCT06224530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
Study: NCT06213857
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An immunosuppressive medication that is used for the treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis). It works by decreasing the activity of the body's immune system so it will not attack itself.
Study: NCT05755386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study: NCT05403827
Drug: K-161
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-161 Ophthalmic Solution
Study: NCT05403827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Solution
Study: NCT06022822
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05358886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05805358
Drug: Hyperpolarized 13C-Pyruvate injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
Study: NCT05095597
Drug: Oestraclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
Study: NCT05565092
Drug: ALXN1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1820 will be administered subcutaneously.
Study: NCT04569435
Drug: ANX005
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05774873
Drug: IBI334 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study: NCT05774873
Drug: IBI334 F
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Study: NCT06280703
Drug: LY3938577
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously (IV)
Study: NCT06280703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously (IV)
Study: NCT06280703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT05468359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide by mouth once daily, Days 1-21
Study: NCT05166161
Drug: PTC923
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Study: NCT05373433
Drug: SSD8432 750mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
Study: NCT05373433
Drug: SSD8432 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
Study: NCT06452433
Drug: gumarontinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg , qd ,po, expect 6 months.
Study: NCT06452433
Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the actual situation of patients. Take as recommended, expect 6 months.
Study: NCT00117065
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04877288
Drug: Enteric Coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04877288
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on Specified days
Study: NCT04625283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo arm will receive intraoperative and postoperative saline.
Study: NCT04823585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution. Subcutaneous.
Study: NCT05145309
Drug: KMgCit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement that provide K, Mg, and citrate
Study: NCT05145309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power with identical appearance to KMgCit
Study: NCT06066515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly subcutaneous injection
Study: NCT06086626
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
Study: NCT06599502
Drug: AZD0022
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.
Study: NCT05245396
Drug: Ref (TF2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
Study: NCT06108050
Drug: JZP898
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug monotherapy
Study: NCT06422936
Drug: BO-112
Normalized name: BOS TAURUS EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
Study: NCT06441630
Drug: AD-227B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study: NCT06441630
Drug: AD-227C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study: NCT06441630
Drug: Placebo of AD-227B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study: NCT06588855
Drug: RO7790121
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
Study: NCT06588855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching IV RO7790121. Placebo matching SC RO7790121.
Study: NCT05178043
Drug: GT90001
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
Study: NCT05378893
Drug: DR10624 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered via subcutaneous injection
Study: NCT05378893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered via subcutaneous injection
Study: NCT04682691
Drug: Erythromycin (400mg)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Erythromycin (400mg)
Study: NCT06497036
Drug: GP404141
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT04841434
Drug: Voraxaze Injectable Product
Normalized name: Voraxaze Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is \>50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing \>100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
Study: NCT03923322
Drug: Botanical Tincture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
Study: NCT05364671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
Study: NCT05775965
Drug: acetylsalicylic acid (ASA) 81mg Oral Tablet
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
Study: NCT06356571
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
Study: NCT04795726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
Study: NCT06770530
Drug: Isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline solution, single dose 200 ml
Study: NCT05600426
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate
Study: NCT05600426
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide
Study: NCT06773962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion.
Study: NCT05223036
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05012618
Drug: LUNA18
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUNA18 Capsule
Study: NCT05156710
Drug: BIVV020 (SAR445088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study: NCT05156710
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: Vary Route of Administration: Vary
Study: NCT06505031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-861-matching placebo tablet.
Study: NCT05761366
Drug: Al18F-PSMA-BCH PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
Study: NCT00240864
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240864
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05831176
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06263673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
Study: NCT06289647
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
Study: NCT06450210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
Study: NCT05644249
Drug: Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
Study: NCT06087536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
Study: NCT06530290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once a day, for 12 weeks
Study: NCT06529796
Drug: IXP
Normalized name: NovoSeven RT with MixPro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT06454188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg tablet once per day.
Study: NCT05730816
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of normal saline.
Study: NCT04891731
Drug: AI or TAM
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.